Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Endocr Relat Cancer. 2019 Jan 1;26(4):425–436. doi: 10.1530/ERC-19-0011

Figure 1. Palbociclib activity in ATC cell lines.

Figure 1.

A, prevalence of RB1 mutations in human ATC. B, Western blot analysis of RB expression in human ATC cell lines. Nthy-ori (non-tumor, immortalized) and FTC133 (follicular thyroid carcinoma) are shown as controls. C, effect of 1 hour treatment with 100nM Palbociclib on RB phosphorylation in two representative ATC cell lines. D,E dose/response analysis of palbociclib effect on the proliferation of human (D) and mouse (E) ATC cell lines.